Nutlin 3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.

Nutlin-3a is arbitrarily referred to as enantiomer a because it appears as the first peak from chiral purification of racemic nutlin-3 and its absolute stereocenter assignment is not known.

Nutlin-3b is 150-fold less potent as an inhibitor of p53-MDM2 interaction than (−)-nutlin-3, demonstrating an IC50 value of 13.6 µM.

NV01 is a small-molecule antagonist of the H3K9me3 binding to UHRF1 tandem tudor domain (TTD) with Kd of 5 uM..

NV03 is a small-molecule antagonist of the H3K9me3 binding to UHRF1 tandem tudor domain with Kd of 2.4 uM..

NVP DPP 728 is a potent and orally active inhibitor of dipeptidyl peptidase (DPP)-IV with Ki and IC50 values of 11 nM and 14 nM, respectively.

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 µM, 0.7

NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.

NVP-AAM077 is a potent antagonist for NMDA receptors.

NVP-ACC789 is an inhibitor of VEGFR-2 (FLK-1/KDR).

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

NVP-AEW541 is a potent inhibitor of IGF-1R with IC50 of 86 nM.

NVP-BAG956(BAG 956) is a potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor in vitro and in vivo,with IC50 values to be 56, 444, 34, 117 and 240 nM for PI3K p110 alpha, beta, delta and gamma and PDK1 kinases, respectively.

NVP-BAW2881 is a novel vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor

NVP-BEP800 is a novel, fully synthetic HSP90β inhibitor with IC50 of 58 nM.

NVP-BGJ398 phosphate (Infigratinib phosphate, BGJ398 phosphate) is a potent, selective pan-FGFR inhibitor with IC50 of 0.9/1.0/1.4/60 nM for FGFR1/2/3/4, also shows high potenct against mutant FGFR3-K650E with IC50 of 4.9 nM.

NVP-BGT226 is a novel dual PI3K/mTOR inhibitor with IC50 of 1 nM.

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.

NVP-BQR695 is a novel PI3K inhibitor.

NVP-BSK805 is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM; >20-fold selectivity towards JAK1, JAK3 and TYK2.

NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.

NVP-CGM097 (CGM-097) is a potent and selective MDM2 inhibitor.

NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

NVP-MELK8a hydrochloride (MELK8a hydrochloride) is a novel potent, and selective MELK inhibitor with IC50 of 2 nM.

NVP-QAV-572 is a potent PI3K kianse inhibitor with IC50 of 10 nM.

NVP-QAV680 is a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.

NVP-TAE684(TAE684) is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.

NVP-TNKS656(TNKS-656) is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2.

NVR 3-778 (NVR3-778, NVR 3778) is a small molecule inhibitor of HBV replication that targets the viral core protein, a first-in-class capsid assembly modulator.

NVS-CRF38 is a potent, selective, orally bioavailable corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50 of 70 nM..

NVS-PAK1-1 potently inhibits autophosphorylation of PAK1 (S144) at 0.25 µM in the Su86.86 cell line and MEK S289 phosphorylation with an IC50 = 0.21 in Su86.86 cells in which PAK2 is downregulated.

NXL101 is a novel quinoline bacterial DNA gyrase and topoisomerase IV inhibitor that shows potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains.

NXY-059 (Cerovive) is an EGFR and HER2 autophosphorylation inhibitor, against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively.

NY0116 (NY 0116) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 27.76 uM for hNMUR1 and 13.61 uM for hNMUR2 in intracellular calcium mobilization assays.

NY-0123 is a novel potent Exchange proteins directly activated by cAMP (EPAC) antagonist with IC50 of 0.9 and 2.4 uM for EPAC1 and EPAC2, respectively.

NY0128 (NY 0128) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 29.99 uM for hNMUR1 and 10.30 uM for hNMUR2 in intracellular calcium mobilization assays.

NY-0173 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 4.0 uM for EPAC1..

NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.

O-1602 (O1602) is an atypical cannabinoid, potent and selective agonist of GPR55 cannabinoid receptor with EC50 of 13 nM, shows no significant activity for CB1 and CB2 receptors (EC50>30 uM).

O304 is a novel AMPK activator.

O4I1-1 is a Oct3/4 inducer. Increases Oct3/4 mRNA levels in HEK293 cells by 2.5- and 4-fold at 10 μM and 20 μM, respectively.

O4I2 is a a new class of small molecules suitable for iPSC generation, showed high activity in enforcing Oct3/4 expression.

OAC1 is a Octamer-binding transcription factor 4 (Oct4)-activating compound; enhances the iPSC reprogramming efficiency and accelerated the reprogramming process.

OAC2 is an Oct4-activating compound which activates expression through the Oct4 gene promoter; enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts; an analog of OAC1.

OADS is a specific, reversible, small-molecule inhibitor directs against CLC (Chloride Channel) antiporter with Ki of 29 uM, has no specific effect on a CLC channel (ClC-1). .

OAT-1746 is a novel potent, selective, orally active inhibitors of Arginase 1 and 2 (ARG1/2) with IC50 of <50 nM.

OAT-177 is a potent, selective, orally active acidic mammalian chitinase (AMCase) inhibitor with IC50 of 14 and 19 nM against human and mouse AMCas, respectively, >150-fold selectivity over mCHIT1.

OAT-2068 is a potent, selective, orally bioavailable inhibitor of mouse chitotriosidase (mCHIT1) with IC50 of 29 nM, 143-fold selectivity over mAMCase.

OBA-09 is a simple ester of pyruvate and salicylic acid, main metabolites of pyruvate and aspirin, respectively, exerts robust neuroprotective effect in the postischemic brain in vivo.

Obatoclax (GX15-070) is Bcl-2 homology domain-3 (BH3) mimetic, antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L).

OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes.

Obicetrapib is a CETP inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy.

OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM.

OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist.

Ochratoxin A demonstrates nephrotoxicity and teratogenesis in animals, and shows inhibition of bacterial, yeast, and liver FARSL (phenylalanyl-tRNA synthetases) competitive with phenylalanine.

Ochratoxin B(OTB) is a non-chlorinated analog of OTA that has cytotoxic effects on kidney and liver cells in vitro but only minor effects in vivo, due to its rapid metabolism and excretion.

Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.

Octahydrocurcumin is a hydrogenated derivatives of curcumin; metabolite of curcumin.

Octopamine (OA), a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates.

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.

Odalasvir (ACH-3102, JNJ-64289901) is a potent, second-generation HCV NS5A inhibitor in development for the treatment of hepatitis C..

Odanacatib (MK 0822) is a potent, selective, and neutral inhibitor of human and rabbit cathepsin K with IC50 of 0.2 nM and 1 nM , respectively.

ODM-201 is a potent and full antagonists for human AR (hAR) with IC50 values of 26 nM by transactivation assays in AR-HEK293 cells.

ODM-203 (ODM203) is a potent, selective, dual inhibitor of FGFR and VEGFR tyrosine kinases with approximately equal potency towards recombinant FGFR1, 2, 3 and 4, as well as VEGFR1, 2 and 3 (IC50=5-35 nM).

ODQ (sGC inhibitor ODQ) is a potent, selective, irreversible inhibitor of sGC (soluble guanylyl cyclase).

OF-1 is a potent inhibitor of BRPF1B and BRPF2 bromodomain with Kd of 100 nM and 500 nM, respectively.

Officinalisinin I is a steroidal saponin, isolated from Anemarrhena asphodeloides.

OGG1 inhibitor O8 is a potent, selective inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 0.22 uM, displays no significant activity against other DNA Glycosylases (NEIL1, NTH1, Fpg, IC50>50 uM)..

OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.

Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.

OGT inhibitor 4a (OSMI-4 active form) is a novel potent, selective O-linked N-acetylglucosamine transferase (OGT) inhibitor with Kd of 8 nM, the active form of OSMI-4..

OHM1 is a potent HIF1α mimic that binds to CH1 domain of p300/CBP with Kd of 500 nM, reduces the level of HIF1α transcriptional activity under hypoxia to that observed under normoxia at 20 uM in A549 cells.

OICR-9429 is a potent and selective chemical probe suitable to help dissect the biological role of WDR5 (Kdisp < 100 nM).

Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, showsthe potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis..

Olanexidine is a monobiguanide compound with bactericidal activity.

Olanzapine(LY170053) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist.

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively.

Olcegepant hydrochloride is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and with a Ki of 14.4 pM for human CGRP.

Olcegepant(BIBN 4096; BIBN 4096BS) is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor(IC50= 0.03 nM).

Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.

Oleuropein is an antioxidant polyphenol isolated from olive leaf.

Oliceridine hydrochloride (Olinvo, TRV130) is a potent, selective, and G protein biased μ opioid receptor (MOR) agonist with pEC50 of 8.1.

Olinone is a selective inhibitor for the BET BRD1 with Kd of 3.4/3.7/8.6 uM for BRD4-BrD1/BRD3-BrD1/BRD2-BrD1, respectively, shows high selectivity over BET BRD2 (Kd>300 uM).

Olmesartan Acid is an angiotensin II receptor antagonist that prevents the binding of angiotensin II, thus preventing vasoconstriction.

Olmesartan medoxomil(Olmetec; Benicar; CS 866) is an angiotensin II receptor antagonist which is used as an anti-hypertensive.

Olodaterol (BI1744) is a long acting β2-adrenoceptor agonist with an EC50 of 1.4±0.08 nM.

Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.

Olopatadine Hydrochloride

Olprinone Hcl(Loprinone Hcl) is a selective phosphodiesterase 3 (PDE3) inhibitor.

Oltipraz is a potent Nrf2 activator and a potent inducer of Phase II detoxification enzymes, most notably glutathione-S-transferase (GST). Phase 3.

Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC).

Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 that could be used in the treatment of acute myeloid leukemia.

Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for the treatment of community-acquired bacterial infections.

Omapatrilat is a dual inhibitor of the metalloproteases ACE and NEP with Ki values of 0.64 and 0.45 nM, respectively.

Ombitasvir is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).

Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors.

Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors.

Omecamtivmecarbil (CK-1827452) is a specific cardiac myosinactivator and a clinical drug for left ventricular systolic heart failure.

Omeprazole(Prilosec) is a proton pump inhibitor used in the treatment of dyspepsia.

Omidenepag is a potent, selective agonist human EP2 receptor with binding IC50/EC50 of 10/1.7 nM, >500-fold selectivity over EP1, EP3 and EP4 receptors; Omidenepag is the active form of Omidenepag Isopropyl (OMDI).

Omidenepag Isopropyl (DE-117, OMDI) is the prodrug of Omidenepag, which is a potent, selective agonist human EP2 receptor; demonstrates excellent IOP-lowering activities following ocular administration in ocular normotensive monkeys, Omidenepag Isopropyl (OMDI) is a clinical candidate for the treatment of glaucoma.

ON 146040 is a potent, dual PI3K/BCR-ABL inhibitor with IC50 of 14/20 nM for PI3Kα/δ , IC50 of 20 nM for BCR/ABL.

ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

ON108110 (ON-108110, ON 108110) is a novel multi-kinase inhibitor of protein kinase CK2 (CK2α1/2, IC50=3/2 nM) as well as CDK4/6 (IC50=2-24 nM).

ON1231320 is a potent selective inhibitor of Polo like kinase 2 (PLK2).

ON123300 is a novel multiple kinase inhibitor.

ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer drug and also a selective agonist of GPR132.

Oncrasin 1 is a proapoptotic substance. Induces abnormal nuclear aggregation of PKCι and suppressing RNA transcription.

Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.

ONO-3080573 is a potent LPA1 inhibitor with IC50 of 11 nM..

ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.

ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase.

ONO-6126 is a potent and selective PDE4 inhibitor for the treatment of bronchial asthma and allergic conjunctivitis..

ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM.

ONO-8590580 is a Novel GABAAα5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models.

ONO-9780307 is a potent LPA1 inhibitor with IC50 of 27 nM..

ONO-9910539 is a potent LPA1 inhibitor with IC50 of 22 nM..

ONO-AE3-208(AE 3-208) is an EP4 antagonist; suppresses cell invasion, migration, and metastasis of prostate cancer.

ONO-DI 004 is a potent, selective EP1 agonist..

ONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus.

OPC-21268 is a vasopressin 1 receptor antagonist potentially for the treatment of heart failure and hypertension.

Opicapone(BIA 9-1067) is a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

Opiranserin (VVZ-149, VVZ-000149) is a potent, selective, mixed glycine GlyT2 transporter blocker (IC50= 0.86 uM), purine P2X3 receptor antagonist (IC50=0.87 uM) and serotonin 5-HT2A receptor antagonist (IC50=1.3 uM).

Oprozomib (ONX 0912) selectively inhibits CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Optovin is a reversible photoactive TRPA1 activator.

OR59402;NSC 48107 is a bioactive compound.

Orally active and specific inhibitor of human hematopoietic prostaglandin D synthase (H-PGDS) (IC50 = 6 μM). Antiallergic and anti-inflammatory.

Org 26576 is a AMPA receptor positive allosteric modulator.

Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased inverse agonist affinity.

Org 42599 is a cell-permeant, allosterically binding, small-molecule agonist of luteinizing hormone (LH) receptor that rescues the folding and cell surface expression mutant mutant human LH receptors A593P and S616Y (EC50=70.8 nM)..

Org 42599 is a cell-permeant, allosterically binding, small-molecule agonist of luteinizing hormone (LH) receptor that rescues the folding and cell surface expression mutant mutant human LH receptors A593P and S616Y (EC50=70.8 nM)..

ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity.

Orita-13 is potent inhibitor of Migration inhibitory factor (MIF) tautomerase activity with Ki of 17 uM..

Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria.

Oritavancin is a semisynthetic glycopeptide antibiotic that inhibits the growth of Gram-positive bacteria.

Orlistat is a drug designed to treat obesity. Orlistat's primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. Orlistat is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

ORM-10962 is a potent, highly selective sodium-calcium exchanger (NCX) inhibitor, significantly reduces inward/outward NCX currents with IC50 of 55 and 67 nM, respectively.

ORM-15341 is a potent and full antagonist for human AR (hAR) with IC50 values of 38 nM as shown by transactivation assays in AR-HEK293 cells stably expressing full-length hAR and an androgen-responsive luciferase reporter gene construct.

Orotic acid (6-Carboxyuracil)

Orvepitant (GW823296) is a potent and selective, brain penetrant NK1 receptor antagonist with pKi of 10.2.

Oseltamivir acid (GS 4071, Ro 64-0802, Oseltamivir carboxylate) is a potent inhibitor of influenza neuraminidase (NA) with Ki of <1 nM for both A and B strains,showed potent activity against COVID-19(SARS-COV-2).

OSELTAMIVIR is an active (orally) inhibitor of the influenze virus neuraminidase and converted to the active acid metabolite in vivo.

OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively.

OSI-420 (Desmethyl Erlotinib,CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for human EGFR and EGFR autophosphorylation in tumor cells.

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R and IR with IC50 of 35 nM and 75 nM, respectively.

OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl.

Osilodrostat is an inhibitor of aldosterone synthase and aromatase, for treating Cushing’s disease.

Osimertinib analogue (C-005) is a potent EGFR inhibitor, which is 2-5 fold more selective than Osimertinib between above EGFR mutants and wild-type EGFR(A431) cells.

OSMI-1 is a cell-permeable, small molecule O-GlcNAc transferase (OGT) inhibitor with IC50 of 2.7 uM.

OSMI-4 (OGT inhibitor 4b) is a novel potent, selective, cell-active O-linked N-acetylglucosamine transferase (OGT) inhibitor with EC50 of ~3 uM.

OSS-128167 is a novel SIRT6 inhibitor.

Ostarine (MK-2866) is a selective androgen receptor modulator (SARMs) that regulates cardiomyocyte function, improves bone healing, regulates uterine function, and influences muscle tissue metabolism.

OSU-03012(AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067.

ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor.

OSW-1 is a natural anti-enterovirus and anti-cancer compound that targets oxysterol-binding protein (OSBP) with Ki of 26 and 54 nM for OSBP and ORP4L, respectively.

Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.

Otenabant (CP945598) is a recently discovered selective, high affinity, competitive CB1 receptor antagonist with Ki of 0.7 nM.

Otilonium Bromide is an antimuscarinic used as a spasmolytic agent.

OTS186935 (OTS-186935) is a potent, in vivo-active inhibitor of protein methyltransferase SUV39H2 with IC50 of 6.49 nM, inhibits A549 cell growth with IC50 of 0.67 uM; causes a significant growth inhibitory effect in mouse xenograft models using MDA-MB-231 breast cancer cells as well as A549 lung cancer cells, at 25 mg/kg once daily for 14 days yielded a TGI of 60.8%; attenuates the levels of H3K9me3 in A549 xenograft mouse model.

OTS193320 (OTS-193320) is a potent inhibitor of protein methyltransferase SUV39H2 with IC50 of 22.2 nM.

OTS-514 is a novel TOPK(PDZ binding kinase; PBK) inhibitor. IC50:2.6nM

OTS964 is a novel TOPK(T–lymphokine-activated killer cell–originated protein kinase) inhibitor.

OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like).

OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like).

OTX008 is a selective inhibitor of galectin-1.

OTX-015 is a new potent BRD2/3/4 inhibitor with evident anti-proliferative activity in several cell lines representative of mature B-cell tumors.

OUL35 (NSC39047) is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of 330 nM, displays remarkable selectivity towards ARTD10 over other enzymes in the human protein family.

OUL35 derivative 32 is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of230 nM, rescues HeLa cells from ARTD10-induced cell death..

OUP-16 is a potent H4R agonist with a considerable selectivity over H3R..

o-vanillin (C29L.

OX-14 is a highly potent farnesyl pyrophosphate synthase (FPPS) inhibitor with IC50 of 2.46 nM, with significantly lower binding affinity to hydroxyapatite.

Oxadiazon is a preemergent herbicide.

Oxaliplatin is a second generation potent platinum-based anti-neoplastic agent that is believed to form inter- and intrastrand DNA adducts which activate signaling pathways culminating in apoptosis. The development of Oxaliplatin was inspired from the eff

Oxamflatin is a potent inhibitor of histone deacetylases (IC50 = 15.7 nM).

Oxcarbazepine inhibits the binding of [3H]BTX to sodium channels with IC50 of 160 μM and also inhibits the influx of 22Na+ into rat brain synaptosomes with IC50 about 100 μM.

Oxfendazole

Oxibendazole

Oxonic acid potassium salt is an inhibitor of uricase, oxonic inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate catalyzed by pyrimidine phosphoribosyl-transferase in a different manner from allopurinol in cell-free extracts and inta

Oxybenzone is a benzophenone derivative used as a sunscreen agent.

Oxybutynin is also a possible treatment of hyperhidrosis (hyper-active sweating) .

Oxythiamine chloride is a small molecule transketolase inhibitor with Kd of 33 nM, shows functional assay of human transketolase inhibition in HCT-116 cells with EC50 of 26 nM.

Oxythiamine, an antimetabolite and a vitamin B1 antagonist, is a well-known thiamine antagonist and inhibitor of transketolase.

Ozagrel HCl

Ozagrel(OKY-046) sodium salt is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.

Ozanimod (RPC1063) is a selective S1P1R modulator

P005091(P5091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM.

P005672 is a phase II drug for antibacterial/anti-inflammatory acne treatment.

P053 (P-053, CerS1 inhibitor P053) is a potent, selective, orally active inhibitor of ceramide synthase 1 (CerS1) with IC50 of 0.5 uM, displays >10-fold selectivity for inhibition of CerS2, CerS4, CerS5, and CerS6.

P22077 is a potent inhibitor of ubiquitin-specific protease (USP) 7 (EC50=8.6 uM), P22077 also inhibits the closely related deubiquitinase (DUB) USP47.

p32 inhibitor M36 is a novel small molecule inhibitor of p32 mitochondrial protein, binds directly to p32 and inhibits p32 association with LyP-1.

p38 MAPK-IN-4 is a potent and selective inhibitor of p38 MAPK with IC50 of 68 nM for p38α, inhibits LPS-induced TNFα release in THP-1 cells with IC50 of 187 nM.

p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1.

p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay.

P516-0475 is a novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO (IC50=10 uM).

P53R3 is a novel p53 reactivator that restores sequence-specific DNA binding of the endogenously expressed p53(R175H) and p53(R273H) mutants in gel-shift assays.

P62-mediated mitophagy inducer (PMI) is a small molecule P62-mediated mitophagy inducer that activates mitophagy without recruiting Parkin or collapsing membrane potential and retains activity in cells devoid of a fully functional PINK1/Parkin pathway.

P7C3-A20 is an analogue of P7C3，a proneurogenic, neuroprotective agent.

PA-824 is an anti-tuberculosis drug for tuberculosis with MIC less than 2.8 μM.Phase 2.

PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation..

PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.